Even as they are gathering proof of extensive benefits to patients, the manufacturers of GLP-1s will have to overcome supply chain difficulties and high prices to get payers to fund these medicines for treating obesity.
Tag Archive for: supply chain
The company said it is already making manufacturing investments for orforglipron, its next-generation oral weight-loss candidate that recently moved into Phase III development.
According to the FDA, Lilly’s Mounjaro is available only in limited quantities through early March 2024.
“We are very pleased with the agreement to acquire the three Catalent manufacturing sites which will enable us to serve significantly more people living with diabetes and obesity in the future,“ said Lars Fruergaard Jørgensen, president and chief executive officer at Novo Nordisk.
The persistent shortage of genuine glucagon-like peptide 1 receptor agonist products has led to an increase in fake versions, the World Health Organization warned on Monday.
According to the FDA’s website, the limit, which is in place through February, is due to an increase in demand.
At the beginning of January, the FDA announced that it was authorizing Florida’s Agency for Health Care Administration to import certain prescription drugs from Canada. Leslie Isenegger, practice leader, corporate pricing and public affairs at Real Chemistry, answers some key questions about the implications the program could have on the pharma industry.
The company said it has not seen any supply issues so far due to Red Sea shipping disruptions, a top executive told Reuters ahead of the World Economic Forum (WEF) on Monday.
According to a survey from August, nearly a third of U.S. hospital pharmacists said that they were forced to ration, delay or cancel treatments as drug shortages in the country approach an all-time high.
2023 was a breakthrough year for cell and gene therapies, with seven FDA approvals in the U.S. and one in the European Union, according to the Alliance for Regenerative Medicine. Looking to 2024, the Washington, D.C.–based advocacy organization predicted that the sector could see up to 17 approvals in the U.S. and EU.